Based onourreviewandanalysis of allcurrentlyavailabledata regarding this potential safetysignal, FDA hasconcluded that treatment with an ARBmedicationdoes notincrease the riskofcancer.
"This is a safetysignal that is really quite similar in magnitude to what happened with Vioxx, " says Steven Nissen of the Cleveland Clinic, who led the analysis.